SRPT250117P145000
- 26.25
- +8.65+49.15%
Sarepta Therapeutics Newsroom
Sarepta, Biogen Drugs With Accelerated Approval Under Fire in FDA Report
Needham Reiterates Buy on Sarepta Therapeutics, Maintains $202 Price Target
Sarepta Therapeutics Analyst Ratings
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $182 to $217
Sarepta Therapeutics (SRPT) Gets a Buy From Piper Sandler
Sarepta Therapeutics: Strong Elevidys Launch and Promising Pipeline Drive Buy Rating
Sarepta Sees Prelim Yr-end 2024 Cash, Cash Equivalents, Restricted Cash and Investments Balance of About $1.5 B >SRPT
Sarepta Announces Q4 2024 Revenue Of $638.2M, Exceeding Guidance; ELEVIDYS Revenue At $384.2M; RNA PMO Revenue At $254M; FY24 Revenue Totals $1.79B; $1.5B In Cash And Investments At Year-End 2024; Reiterates 2025 Revenue Guidance Of $2.9B-$3.1B
Sarepta Therapeutics Preliminary ELEVIDYS Net Pdt Rev Totaled $384.2 M in 4Q >SRPT
Sarepta Therapeutics: Preliminary Total Net Pdt Rev of $638.2M for the 4Q >SRPT
Express News | Sarepta Therapeutics Inc - Reiterates 2025 Revenue Guidance of $2.9-$3.1 Bln
Express News | Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
Express News | Sarepta Therapeutics Q4 Revenue USD 638.2 Million Vs. IBES Estimate USD 585.1 Million
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $195
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Sarepta Therapeutics: A Promising Investment With Strategic Market Position and Innovative ARO-DM1 Program
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $165
RBC Cuts Price Target on Sarepta Therapeutics to $165 From $182, Keeps Outperform Rating